BRIT1 allows DNA repair teams access to dam... ( HOUSTON

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

BRIT1 allows DNA repair teams access to damaged sites

Date:6/19/2009

HOUSTON - Like a mechanic popping the hood of a car to get at a faulty engine, a tumor-suppressing protein allows cellular repair mechanisms to pounce on damaged DNA by overcoming a barrier to DNA access.

Reporting online at Nature Cell Biology this week, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center shows that BRIT1 connects with another protein complex to relax DNA's tight packaging at the site of the damage.

"Relaxing this barrier allows two different DNA repair pathways greater access to the damage, preventing flawed DNA from being passed on as the cell divides, which causes genomic instability leading to cancer," said senior author Shiaw-Yih Lin, Ph.D., assistant professor in M. D. Anderson's Department of Systems Biology.

BRIT1 is under-expressed in human ovarian, breast and prostate cancer cell lines. Lin and colleagues previously showed that the protein plays a key role in early detection of DNA damage.

Chromosomes are made of DNA that is tightly intertwined with proteins called histones to form chromatin. Chromatin is a very condensed structure that forms a natural barrier inhibiting access to genes, said first author Guang Peng, Ph.D., a post-doctoral fellow in Systems Biology. ATP-dependent chromatin remodeling is a fundamental mechanism used by cells to relax chromatin in DNA repair, but the detailed molecular mechanism by which it is recruited to DNA lesions in response to damage signaling has been largely unknown.

BRIT1 summons help

"Our studies demonstrate a novel mechanism by which BRIT1 recruits chromatin remodeling factors to DNA lesions to facilitate chromatin relaxation and DNA repair," Peng said.

A series of lab experiments showed that BRIT1 accomplishes this by enhanced binding to a known chromatin remodeling complex called SWI-SNF when a specific site on the complex is phosphorylated. BRIT1 also maintains the relaxat
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home
2. Microgrid allows simultaneous study of multiple variables
3. Computer simulator allows visually-impaired to drive
4. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
5. Anesthesia Pouch Allows Children to Go Home Sooner After Surgery
6. A new method allows for the early diagnosis of pulmonary hypertension
7. Mapping tool allows emergency management personnel to visually track resources
8. Elseviers "WiserWiki" Allows Physicians to Update Evidence-Based Medical Information With Experience-Based Practice Insights
9. Elseviers WiserWiki allows physicians to update evidence-based medical information
10. U.S. Patent Office Allows Significant New VNUS Patent
11. U.S. Patent Office Allows Another Significant VNUS Patent

Post Your Comments:

[0] Blood Thinner Combos Risky for Heart Attack Patients [0] Centegra Expands H1N1 Vaccines to General Public [0] Do Charitable Gift Donations Make a Difference?[0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [0] Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security

Most Kidney Donors Lead Long, Healthy Lives NBTY Reports First Quarter Results Medical College of Wisconsin recognized for AIDS intervention research CCA Industries, Inc. Declares Dividend For The First Quarter Covance Reports Fourth Quarter and Full-Year 2008 Results Toxic Causation Training Day for Attorneys

Breaking Medicine Technology:Within3 Expands into Mobile Applications 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2 RecoverCare and MedaSTAT USA Complete Transaction 53601 1 RecoverCare and MedaSTAT USA Complete Transaction 53601 2 RecoverCare and MedaSTAT USA Complete Transaction 53601 3 BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1 BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2 AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1 AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2

[0] Within3 Expands into Mobile Applications [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program

Other Medicine Technology:Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 2 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 3 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 4 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 5 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

Medicine Products:

FlexNet™Spot Vital Signs 3800 Pulse Oximeter with TruTrak+ Technology 3775 Handheld Pulse Oximeter

BRIT1 allows DNA repair teams access to dam...( HOUSTON - Like a mechanic popping th...),Health